Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Disease Progression
Gènes
Inflammatory bowel diseases
DNA methylation
IBD
Over 80s
Acceptability
Stricture
Therapeutics
Methylation
Cancer
Endoscopic treatment
Inclusion
Crohn's disease
Dysbiosis
Colorectal cancer
Disability
Cost effectiveness
Drug
Tuberculosis
Biomarker
Heart disease risk factors
Patient-reported outcome
Immunosuppressant
18 FDG-PET/CT
Survival
MICROBIOTA
Monitoring
Colorectal cancer Colibactin and lipids
Genes
T1118 translocation
Colon cancer
Safety
Inhibitor
CARCINOGENESIS
MALT
MORTALITY
Immune cells
Original Article Clinical
Ustekinumab
Consensus
Clinical trial
Bacteria
Gene methylation
Gene expression
Neoadjuvant chemotherapy
Colon
Bactéries
Primary sclerosing cholangitis
Microbiote
Inflammatory Bowel Diseases
Eligibility
Alkylating agents
Disease progression
Venous thromboembolism
Cell adhesion
IL23
Clinical guidelines
Colonic epithelial primary cells
Ulcerative colitis
IL12
Dysbiose
Inflammatory bowel disease
Rituximab plus chlorambucil
Epigénétiques
Crohn’s disease
Upper gastrointestinal tract
Screening
Maintenance therapy
Tailored therapy
Biologics
COLON-CANCER
Contraindication
Colectomy
DNA METHYLATION
Microbiota
Effectiveness
Anti-TNF agents
RISK
Epigenetics
Kidney diseases
Fecal microbiota
Méthylation
Thérapie ciblée
Algorithm
Helicobacter pylori
Resistance
Eradication
HIV
Rituximab
MARKER
Small molecules
PCR
Intestinal crypts
Surgery
Patients experience
Résistance
Parvimonas micra
Anti-TNF
Vedolizumab
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|